EKRA Compliance for Treatment Centers: What You Need to Know in 2026

If you operate a treatment facility and you're trying to figure out which of your current marketing arrangements expose you to federal criminal liability, you're not alone. The Eliminating Kickbacks in Recovery Act has been on the books since 2018, but enforcement intensified meaningfully in the last 24 months, and structures that were standard practice across the industry now carry real prosecution risk.

This guide is what we'd want a treatment center owner to read before making any new marketing decisions in 2026. It covers what EKRA actually prohibits, how state-level patient brokering laws compound the federal exposure, what marketing structures hold up under scrutiny, and what specific contract language and arrangements should make you immediately reconsider a vendor relationship.

We're not lawyers, and this isn't legal advice. We operate addiction treatment directories and have spent a considerable amount of time understanding EKRA because our business model depends on staying on the right side of it. What follows is the operator's view of compliance, not a legal opinion. Talk to actual counsel before making decisions on specific arrangements.

Quick note: If you've already decided your current marketing setup needs to change and you want to look at flat-fee directory inventory as an alternative, check availability in your states here. Otherwise, keep reading.

What EKRA actually says

The Eliminating Kickbacks in Recovery Act (18 U.S.C. § 220) was passed in 2018 as part of the SUPPORT for Patients and Communities Act. It was designed to address a specific problem: treatment centers and recovery homes paying marketers, body brokers, and lead generators based on the number of patients delivered, with payments often scaling based on insurance type or treatment duration.

The statute prohibits, with respect to services covered by a health care benefit program, knowingly and willfully:

Soliciting or receiving any remuneration (including any kickback, bribe, or rebate) directly or indirectly, overtly or covertly, in cash or in kind, in return for referring a patient to a recovery home, clinical treatment facility, or laboratory; or

Paying or offering any remuneration to induce a referral or in exchange for an individual using the services of a recovery home, clinical treatment facility, or laboratory.

The penalties are severe. Convictions carry potential fines up to $200,000 per violation and imprisonment up to 10 years.

A few specific things about the statute matter for marketing decisions:

The "remuneration" language is broad. It captures cash, anything-of-value transfers, percentage-of-revenue arrangements, and effectively any compensation structure that creates a financial relationship between the referrer and the facility receiving the patient. The breadth is intentional — Congress wrote the statute specifically to capture creative structures the addiction treatment industry had developed.

The "in return for referring a patient" language is critical. The statute targets payments tied to patient referrals, not payments for marketing services in general. This is the structural distinction that determines whether a marketing arrangement is exposed or clean. Payment for access (advertising space, marketing services, agency retainers) is generally fine. Payment for outcomes (calls, leads, VOBs, admits) is generally exposed.

There are statutory exceptions, but they're narrow. The statute has carve-outs for legitimate employment relationships, certain payments by health plans, federally qualified health centers, and a few other categories. None of the standard exceptions cover the typical agency or lead-gen arrangement that treatment facilities encounter.

Federal jurisdiction is broad. EKRA applies to any service paid for by a "health care benefit program," which includes virtually all commercial insurance, Medicare, Medicaid, and self-pay arrangements that touch federally-related health programs. Practical effect: if your facility takes any insurance at all, EKRA applies to your marketing.

How EKRA differs from the federal Anti-Kickback Statute

A common misunderstanding in the treatment industry conflates EKRA with the federal Anti-Kickback Statute (AKS). The two statutes overlap but have important differences that affect how compliance decisions get made.

The Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)) applies broadly to federal health care programs (Medicare, Medicaid, etc.). EKRA applies more broadly to "health care benefit programs" which includes commercial insurance.

The AKS has a robust set of regulatory safe harbors that protect specific arrangement structures. Compliance attorneys have spent decades building defensible structures within those safe harbors. EKRA does not have an equivalent regulatory safe harbor framework. The statutory exceptions exist, but the detailed regulatory guidance that exists for the AKS hasn't been built out for EKRA.

The practical implication: structures that have historically been defended under AKS safe harbors may not be defensible under EKRA. An arrangement that your AKS-focused attorney signed off on in 2017 may carry meaningful EKRA exposure in 2026 because EKRA effectively expanded the prohibition without expanding the safe harbors.

If you have existing marketing arrangements and a compliance opinion that predates 2020 or relies primarily on AKS safe harbor analysis, the opinion may not address your current EKRA exposure adequately. Re-review by counsel familiar with EKRA specifically is a defensible investment.

State-level patient brokering laws

Federal EKRA is the floor, not the ceiling. Several states have enacted their own patient brokering laws that further restrict treatment marketing arrangements, and those state laws often capture conduct that EKRA might not reach.

Florida § 817.505 is the most actively enforced state patient brokering statute. Originally enacted in 2017 and strengthened in subsequent revisions, it prohibits offering, paying, soliciting, or receiving anything of value in exchange for referring a patient to a treatment facility. Violations are felonies. Florida prosecutors have been particularly active, and several cases have resulted in convictions of facility owners, marketers, and intermediaries.

Arizona enacted HB 2502 in 2019. It prohibits patient brokering for substance use disorder treatment with criminal penalties.

California has multiple statutes that touch on this area, including amendments to Health and Safety Code provisions affecting recovery residences and treatment facilities. The state has been progressively tightening regulation of treatment marketing.

Tennessee, Utah, Massachusetts, New York, and Indiana have all enacted patient brokering provisions, though enforcement levels vary.

The patchwork creates a compliance complication that operators sometimes underestimate. A marketing arrangement structured to comply with federal EKRA may still violate state law, and the state laws aren't uniform — what's permitted in Texas may be prohibited in Florida.

For treatment centers operating in multiple states or marketing across state lines, the practical compliance posture has to be the most restrictive applicable law. If your patients come from Florida, Florida law applies regardless of where your facility sits.

What marketing structures are exposed

Here's an honest accounting of which common treatment marketing arrangements carry the most EKRA exposure:

Per-call payment to lead generators. Highest exposure. The structure directly trades payment for patient referrals. Lead-gen platforms argue various theories of compliance — that calls aren't referrals, that the calls are non-specific, that the payment is for marketing services rather than patients — but the structures haven't held up well in actual prosecutions.

Per-admit bonuses or quotas. Highest exposure. Even if the base relationship is structured as a flat fee, performance-based bonuses tied to admissions add per-unit compensation that creates EKRA risk.

Percentage of revenue arrangements. Highest exposure. Marketing agencies or lead generators paid as a percentage of the revenue their work produces have direct economic alignment with patient volume, which is structurally identical to the prohibition.

Cost-per-acquisition (CPA) marketing. Mixed. CPA structures that pay per patient admission carry similar exposure to per-admit bonuses. CPA structures that pay per inquiry or per-form-fill are closer to standard advertising compensation but still raise questions about how "acquisition" is defined.

Body brokers and patient placement services. Highest exposure. Direct-to-patient referral relationships where the broker receives payment when the patient enters treatment are exactly what EKRA was designed to address.

Lead-share platforms with variable pricing. Significant exposure. Platforms that adjust pricing based on lead quality, conversion, or downstream value create variable compensation tied to outcomes, which creates EKRA risk.

Affiliate marketing arrangements. High exposure. Affiliate compensation tied to patient enrollments or admissions is structurally similar to prohibited arrangements.

Pay-per-call platforms with IVR routing. Mixed-to-high exposure. Even when calls are filtered through a buffer or IVR before transfer, the underlying payment-per-call structure creates EKRA exposure that hasn't been resolved by industry argument.

What marketing structures are clean

Several structures have generally held up as defensible under EKRA, though all benefit from careful contract language and counsel review:

Flat-fee marketing services with no per-unit components. Marketing agencies on monthly retainers for specific deliverables (campaign management, SEO work, content creation, GBP management) without per-call, per-lead, or per-admit components are generally compliant. The retainer must reflect fair market value for the services actually provided, and shouldn't escalate based on patient volume.

Direct paid advertising. Running ads on Google, Facebook, or other platforms where the facility itself pays the platform directly for ad placement is straightforward. The facility is paying for advertising access, not for referrals.

Flat-fee directory placement. Renting placement on a directory site for a fixed monthly fee, without per-call, per-VOB, or per-admit components, is generally clean. The arrangement is structurally equivalent to renting a billboard or buying a magazine ad.

Owned-asset SEO and content investment. Investing in your own facility's website, SEO, content, and owned channels creates assets you own outright. There's no third-party payment relationship to worry about.

Professional services paid hourly or by deliverable. Consultants, copywriters, designers, and developers paid hourly or by project for specific deliverables, with no patient-volume-related compensation, are generally fine.

Salaried employees doing marketing. Internal employees paid salary for marketing work fall under the statutory employment exception.

The common thread: payment is tied to access, services, or assets — not to patient outcomes. When you can answer "what am I paying for, specifically" with a list of deliverables, services, or rented spaces rather than "patients delivered to my facility," you're generally on the right side of the line.

How to vet a marketing vendor for EKRA exposure

If you're evaluating a new marketing vendor or auditing an existing relationship, several questions reliably surface compliance issues.

1. Walk me through exactly what I'm paying for and how the payment is calculated.

A vendor with a clean structure can answer this in two sentences: monthly retainer for X services, or flat fee for Y placement, or hourly billing for Z work. A vendor with an exposed structure starts qualifying immediately and brings in concepts like "performance-based" or "ROI-aligned" or "we share the upside."

2. Does any portion of my payment vary based on calls, leads, VOBs, or admissions?

The honest answer should be "no." Variable-based-on-outcomes is exactly what EKRA targets.

3. Can I see your standard contract?

Vendors with confidence in their structure share contracts willingly. Vendors who've structured exposure into their contracts often resist sharing or insist on heavy customization that obscures the structure.

4. What does your contract say about EKRA specifically?

Strong vendor contracts include explicit EKRA acknowledgment and structural commitments — language confirming the compensation is for services rendered rather than referrals, that no per-patient compensation exists, etc. Weak contracts are silent on EKRA or contain ambiguous language.

5. Have you had your contract reviewed by counsel familiar with EKRA, and would you be comfortable if I did the same?

A confident vendor invites your legal review. A nervous vendor discourages it or argues that the contract is "standard" and review isn't necessary.

6. What's your geographic and category exclusivity?

This isn't directly an EKRA question but it surfaces conflict-of-interest issues. A lead-gen vendor selling the same calls to multiple facilities has implicit incentives to maximize volume rather than quality, which often correlates with the structures EKRA targets.

If a vendor can't or won't answer these questions clearly, the relationship has issues you'd need to resolve before signing.

Specific contract language to watch for

When reviewing vendor contracts, certain language patterns reliably indicate exposure:

Watch for:

"Performance-based fees"
"Per-call rate"
"Per-lead pricing"
"Per-admit bonus"
"Cost-per-acquisition"
"Revenue share"
"Percentage of treatment revenue"
"Tiered pricing based on results"
"Success fee"
"Conversion bonus"

Look for:

"Flat monthly fee"
"Fixed retainer"
"Hourly billing rate"
"Project fee"
"Placement rental"
"Advertising fee"
"No portion of compensation is contingent on patient volume, calls, leads, verification of benefits, or admissions"

The second list isn't a magic shield, but it's the structural foundation of a defensible arrangement. The first list isn't automatically illegal in every context, but it's the structural foundation of arrangements that have produced enforcement actions.

What to do about existing arrangements that look exposed

If you're reading this and realizing one or more of your current marketing arrangements has structural EKRA exposure, you have a few options.

Immediate review by counsel. Before doing anything else, get a current EKRA-aware compliance review of the specific arrangement. Some arrangements that look exposed on the surface have specific contractual or operational details that mitigate the exposure. Others don't. Counsel can help you understand which category yours fall into.

Restructure rather than terminate. Many vendors will agree to restructure their arrangement to a flat-fee or retainer basis if pushed. The math may change — the vendor may charge more on a flat-fee basis than they would on a per-call basis — but the compliance exposure goes away. This is often the cleanest path forward.

Terminate and replace. If the vendor is unwilling to restructure, or if the relationship has been operationally problematic anyway, termination and replacement is the cleaner option. Build the replacement around a vendor with structurally compliant pricing.

Document the transition. Whatever path you take, document the analysis, the decisions, and the actions taken. Compliance posture is partly about what you actually do and partly about what you can demonstrate doing in the event of inquiry.

Why we built our directory rental model the way we did

Full transparency: we operate addiction treatment directories and rent state-level pages to facilities on a flat monthly fee basis. The structure is no per-call, per-VOB, or per-admit components — strictly flat advertising rental. We chose this model specifically because it puts us and our facility partners in a defensible position under both EKRA and the most restrictive state patient brokering laws.

The economic case for the structure is straightforward. We'd rather have a long-term partner who renews indefinitely on a clean compliance basis than a short-term arrangement that creates legal risk for either side. Flat-fee rentals make the relationship sustainable.

If you're auditing your marketing arrangements and want to evaluate flat-fee directory inventory as a replacement for exposed structures, check availability in your states here. State-level pricing is published transparently, contract structure is straightforward, and we'd rather you have your own counsel review the agreement than for either of us to be surprised later.

The bottom line on EKRA

EKRA is real, enforcement is real, and structures that were standard a few years ago carry meaningful exposure today.

The compliance principle is structural and applicable without specialized legal training: payment for access, services, and assets is generally fine. Payment tied to patient outcomes (calls, leads, VOBs, admissions) generally isn't.

The implications for treatment center marketing decisions are concrete:

Audit your current marketing arrangements through this structural lens
Get counsel review of anything that doesn't pass the structural test
Restructure or replace exposed arrangements before they become liabilities
Build new arrangements on flat-fee, services-based, or asset-based foundations
Document the analysis and the decisions

The cost of getting EKRA wrong is severe enough that the compliance posture deserves the same operational attention that clinical compliance, billing compliance, and accreditation receive. Most treatment centers handle clinical compliance with rigor and marketing compliance with hope. The risk profile doesn't justify that gap.

If you're working through marketing decisions and want to understand the broader landscape of channels and unit economics across treatment center marketing, our complete guide to rehab marketing in 2026 covers the full picture. If you want to walk through how flat-fee directory rental compares to your current arrangements specifically, submit a quick application and our team will follow up with availability and pricing for your states.

Disclaimer: This article provides general information about EKRA and related state laws. It is not legal advice. EKRA enforcement and compliance analysis depend on specific facts and circumstances. Treatment center operators should obtain advice from counsel familiar with EKRA and applicable state laws before making decisions about specific marketing arrangements.